XML 115 R74.htm IDEA: XBRL DOCUMENT v3.23.2
Research and License Agreements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 06, 2023
Mar. 29, 2023
Feb. 21, 2023
Feb. 28, 2019
Sep. 30, 2018
Dec. 31, 2016
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dr. Langer                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
Payment to director               $ 11 $ 6
MIT                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
Description of future development obligations               The Company’s future development obligations are: (i) to commence a Phase 3 clinical trial for such Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such Product.  
License fee payment           $ 50      
Percentage of shares of common stock issued           5.00%      
Description of conditions to terminate license agreement             The Company has the right to terminate for any reason upon a 3-month prior written notice. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.  
Right to terminate agreement upon prior written notice           3 months      
Right to terminate agreement if breach remains uncured           90 days      
Right to terminate agreement incase of nonpayment           30 days      
Right to terminate agreement upon prior written notice if insolvent 3 months                
MIT | Maximum                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
Milestone payments           $ 2,900      
MIT | Patent License Agreement                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
License agreement entered date           2016-12      
CALIBR                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
License fee payment         $ 1,000        
Percentage of Royalty on Sublicense Revenue         50.00%        
Milestone payments         $ 26,000        
Description of conditions to terminate license agreement   the Company sent CALIBR a notice stating that the Company would be terminating the CALIBR License Agreement in 30 days’ time.           The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.  
Right to terminate agreement if breach remains uncured   30 days     30 days        
Right to terminate licensed patents upon prior written notice         90 days        
CALIBR | Patent License Agreement                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
License agreement entered date         2018-09        
MEE                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
License fee payment       $ 20          
Description of conditions to terminate license agreement     the Company sent MEE a notice stating that the Company would be terminating the MEE License Agreement in 30 business days’ time.         The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days  
Right to terminate agreement upon prior written notice       30 days          
Right to terminate agreement if breach remains uncured     30 days 60 days          
Right to terminate agreement incase of nonpayment       30 days          
Right to terminate agreement upon prior written notice if insolvent       45 days          
MEE | Maximum                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
Milestone payments       $ 350          
Annual License Fee Per Share             $ 7.5 $ 7.5  
MEE | Minimum                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
Royalty Expense Per Share               15  
Annual License Fee Per Share             $ 5 $ 5  
MEE | Non-Exclusive Patent License Agreement                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                  
License agreement entered date       2019-02